Fig. 7

SPRYD4 over-expression inhibits tumor growth in vivo. A BALB/c-nudes (n = 6 per group) were sacrificed 50 days after the injection and tumors dissected from respective groups were shown. B Tumor growth curves after the injection of HUCCT1/SPRYD4-OV and control cells. Tumor volume was calculated every 10 days. C Tumor weight was measured in SPRYD4-OV and control groups. D IHC staining of SPRYD4, Ki67 and Tunel in tumors from SPRYD4-OV and control groups. Scale bars: 200 μm. P-values were assessed using two-tailed t-tests and ANOVA followed by Dunnett’s tests for multiple comparison in B-C. All ** P-value < 0.01, *** P-value < 0.001